Rationale: The number of patients with coronary heart disease, including myocardial infarction, is increasing and novel therapeutic strategy is awaited. Tumor suppressor protein p53 accumulates in the myocardium after myocardial infarction, causes apoptosis of cardiomyocytes, and plays an important role in the progression into heart failure. Objectives: We investigated the molecular mechanisms of p53 accumulation in the heart after myocardial infarction and tested whether anti-p53 approach would be effective against myocardial infarction. Methods and Results: Through expression screening, we found that CHIP (carboxyl terminus of Hsp70-interacting protein) is an endogenous p53 antagonist in the heart. CHIP suppressed p53 level by ubiquitinating and inducing proteasomal degradation. CHIP transcription was downregulated after hypoxic stress and restoration of CHIP protein level prevented p53 accumulation after hypoxic stress. CHIP overexpression in vivo prevented p53 accumulation and cardiomyocyte apoptosis after myocardial infarction. Promotion of CHIP function by heat shock protein (Hsp)90 inhibitor, 17-allylamino-17-demethoxy geldanamycin (17-AAG), also prevented p53 accumulation and cardiomyocyte apoptosis both in vitro and in vivo. CHIP-mediated p53 degradation was at least one of the cardioprotective effects of 17-AAG. Conclusions: We found that downregulation of CHIP level by hypoxia was responsible for p53 accumulation in the heart after myocardial infarction. Decreasing the amount of p53 prevented myocardial apoptosis and ameliorated ventricular remodeling after myocardial infarction. We conclude that anti-p53 approach would be effective to treat myocardial infarction. (Circ Res. 2010;106:1692-1702.) 
T he number of patients with coronary heart disease has been increasing and cardiovascular diseases are the leading cause of deaths in the Western world. Despite the development of pharmacological and nonpharmacological interventions, 33% of the men and 43% of the women die within 5 years after myocardial infarction (MI). 1 Therefore, a novel therapeutic approach against coronary heart disease is awaited.
Apoptosis of cardiomyocytes is accompanied with acute coronary occlusion. 2 Because apoptotic loss of cardiomyocytes causes heart failure, 3 inhibition of apoptosis has been suggested as an additional therapeutic approach to coronary heart disease. 4 In mice, overexpression of antiapoptotic Bcl-2 protein or genetic deletion of proapoptotic Bax protein have been reported to prevent apoptosis and reduce infarct size, [5] [6] [7] [8] implicating that antiapoptotic approach is effective for prevention of ventricular remodeling after myocardial infarction.
The tumor suppressor p53 is an important transcription factor that regulates cell cycle progression, cellular senescence, and apoptosis. Under physiological condition, p53 protein level is maintained low, but is elevated when cells are stressed or damaged. 9 The mechanism for keeping p53 protein level low involves several E3 ubiquitin ligases such as MDM2, 10, 11 COP1, 12 and Pirh2. 13 Importantly, the expression of these proteins were positively regulated by p53, suggesting the role for negative-feedback loop against p53 elevation.
Protein level of p53 is also kept low in the heart but it is elevated when cardiac cells are exposed to hypoxia. 14 -16 We have recently reported that elevation of p53 causes the development of pressure overload-induced heart failure. 16 We have also observed the elevation of p53 protein levels after myocardial infarction and shown that p53 gene deletion improved cardiac function after myocardial infarction, 16 suggesting that the inhibition of p53 might become a novel therapeutic strategy for ischemic heart diseases.
As an initial approach for the investigation of anti-p53 therapy, we searched for an endogenous p53 antagonist in the heart. Through expression screening, we found that CHIP (carboxyl terminus of Hsp70-interacting protein) is an endogenous p53 antagonist that keeps p53 level low in the heart. We also found that CHIP downregulation is involved in the mechanism of p53 accumulation in the heart after myocardial infarction. Facilitating CHIP-mediated p53 degradation prevented apoptosis of cardiomyocytes and ameliorated ventricular remodeling in the postinfarct heart. The present study revealed the mechanism of p53 accumulation in the heart after myocardial ischemia and suggested that anti-p53 approach would be effective to treat myocardial infarction.
Methods Expression Cloning
Expression cloning was performed as described previously 17 using PG13-Luc (kind gift from B. Vogelstein, Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute, and Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Md) as a reporter plasmid. Initially, cDNA expression library from human heart (Invitrogen) was separated into small pools that contain Ϸ100 clones each. cDNA clones that downregulate PG13 activity were isolated by sib-selection.
Cell Culture
COS7 and HEK293 cells are from ATCC and cultured in DMEM containing 10% FBS (Invitrogen). Neonatal rat cardiomyocytes were isolated from 1-day-old Wistar rats and cultured as described previously. 18 Cardiomyocytes were exposed to hypoxic stress by culturing under CoCl 2 or by culturing in hypoxic chamber (Ͻ1% O 2 ; PO 2 , 18 to Ϸ20 mm Hg).
Animals
All protocols were approved by Chiba University review board. CHIP knockout mice and cardiac-specific inducible hypoxiainducible factor (HIF)-1 knockout mice were described. 16, 19, 20 Heterozygous CHIP knockout mice were used in this study because homozygous knockout mice were perinatally lethal. 20 Cardiacspecific CHIP transgenic mice were generated by pronuclear injection of ␣MHC-HA-CHIP transgene construct. Coronary artery ligation was performed on 10-week old male mice as described previously. 21
Statistical Analysis
Data are expressed as meansϮSE. The significance of differences among means was evaluated using analysis of variance (ANOVA), followed by Fisher's protected least significant difference test and Dunnett's test for multiple comparisons. Significant differences were defined as PϽ0.05.
Results

Identification of CHIP As a Novel p53 Antagonist From Heart cDNA Library
To elucidate novel p53 antagonists in the heart, we performed expression screening by expressing cDNA pools in COS7 cells together with a reporter plasmid, PG13-luciferase, which contains 13 copies of p53 binding site upstream of luciferase gene and responsive to wild-type p53 dependent transcription. From the screening of 500 cDNA pools, each containing around 100 individual cDNA clones obtained from human heart cDNA library, we found 5 pools that suppress the PG13 activity. Individual cDNA clone that downregulates the PG13 activity was identified by sibselection. One of the molecules that was highly expressed in the heart ( Figure I , A, in the Online Data Supplement, available at http://circres.ahajournals.org) was CHIP (also called STUB1 [Stip1 homology and U-box containing protein]), a chaperone-interacting protein with E3 ubiquitin ligase activity. 22 Transfection of CHIP suppressed endogenous and exogenous (by overexpression of p53) PG13 activity ( Figure 1A ) and decreased the protein levels of p53 ( Figure 1B ) in a plasmid dose-dependent manner in COS7 cells. Direct interaction between CHIP and p53 was confirmed both at the exogenous level in COS7 cells (Online Figure I Figure I , E), indicating that CHIP directs p53 for proteasome-mediated degradation. When CHIP was knocked down in cardiomyocytes using small interfering (si)RNA, p53 expression was upregulated ( Figure 1C ), and p53 protein levels following CHIP knockdown were comparable to those induced by the knockdown of MDM2, a well known E3 ubiquitin ligase for p53 ( Figure 1D ). CHIP protein level was not changed by knockdown of MDM2 ( Figure 1D ). p53 protein levels were also markedly elevated in the heart of CHIP heterozygous mice ( Figure 1E ). These results suggest that CHIP induces degradation of wild-type p53 protein in cardiomyocytes, which is consistent with previous reports in other cells (H1299 cells and U2OS cells). 23, 24 In addition, we revealed that CHIP is a crucial negative regulator that keeps p53 protein levels low in the heart under physiological conditions. 
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Molecular Mechanisms of Hypoxia-Induced p53 Accumulation
As CHIP regulates p53 status in the heart, we speculated that CHIP might be involved in the molecular mechanism of hypoxia-induced p53 accumulation in the heart. Cobalt chloride (CoCl 2 ) increases HIF-1 activity through preventing HIF-1␣ protein degradation and is widely used as a hypoxia mimicking reagent. 25, 26 Treatment of cardiomyocytes with CoCl 2 (250 mol/L) increased p53 protein level with a marked downregulation of CHIP protein level ( Figure 2A) . Notably, the expression of MDM2 was rather increased in this experimental condition. Because transcriptional regulation of MDM2 is known to be upregulated by p53 as a part of negative-feedback loop, increased MDM2 expression after CoCl 2 treatment may possibly be attributable to this feedback system against p53 elevation. Accumulation of p53 and downregulation of CHIP were also observed when cardiomyocytes were cultured in hypoxic chamber for 24 hours (Online Figure I, F ). We confirmed that both treatments increased nuclear HIF-1␣ protein that binds to HIF-1␣ binding oligonucleotide by commercially available ELISA system (Online Figure I , G). We also analyzed the expression of p53 and CHIP in the heart after MI. p53 protein levels were increased on day 1 after MI and remained upregulated thereafter, whereas expression levels of CHIP were markedly downregulated on day 1, and remained at lower levels than those of controls ( Figure 2B and analyzed in Online Figure II , A and B). In contrast, MDM2 protein levels were slightly increased after MI ( Figure 2B ). The inverse correlation between CHIP and p53 protein level implies the possible involvement of CHIP downregulation in the initiation of p53 accumulation after acute hypoxic stress. Other E3 ubiquitin ligases whose transcription is regulated by p53, such as MDM2, might work to reverse p53 level after initial accumulation of p53 as a feedback system to prevent further detrimental effects that might be elicited by chronic p53 elevation.
To investigate why CHIP is downregulated after hypoxic insult, we tested whether HIF-1 mediates hypoxia-induced downregulation of CHIP, because HIF-1 is known to downregulate some of its target genes through hypoxia-responsive element (HRE). [27] [28] [29] [30] Human CHIP promoter (from Ϫ329 bases upstream of transcription start site to ϩ39 bases downstream of transcription start site) that contains a conserved HRE at Ϫ49 ( Figure 2C ) was cloned upstream of luciferase reporter gene (pGL4-CHIP). pGL4-CHIP activity was significantly suppressed by both CoCl 2 treatment (24 hours) and HIF-1␣ overexpression in COS7 cells ( Figure  2D ). When a mutation was introduced into HRE at Ϫ49 (pGL4-CHIP-mutHRE), the luciferase activity was no longer responsive to hypoxic stress or HIF-1␣ overexpression ( lated by HIF-1 at the transcriptional level through HRE. Real-time PCR analysis revealed that exposure of cardiomyocytes to CoCl 2 (24 hours) and adenoviral overexpression of constitutively active HIF-1␣ led to marked downregulation of CHIP mRNA levels ( Figure 2E ), further supporting our data that hypoxic stress downregulates CHIP levels. HIF-1␣ gene is both required and sufficient for hypoxic stress-induced CHIP downregulation and p53 accumulation because knockdown of HIF-1␣ attenuated the effects of CoCl 2 treatment on expressions of p53 and CHIP (Online Figure III, A) , and overexpression of constitutively active HIF-1␣ suppressed CHIP expression and increased p53 expression in cardiomyocytes (Online Figure III, B ). Furthermore, downregulation of CHIP protein levels after MI was attenuated in cardiacspecific inducible HIF-1␣ conditional knockout mice 16 (Online Figure III, C). Collectively, these findings suggest that CHIP transcription is directly downregulated by hypoxia through HIF-1.
CHIP Protects Cardiomyocytes From Hypoxia-Induced p53-Mediated Apoptosis of Cardiomyocytes
Because hypoxia or p53 overexpression induces apoptotic cell death in cultured cardiomyocytes, 14 cardiomyocytes ( Figure 4A through 4C) . These results underscore our hypothesis that downregulation of CHIP is responsible for p53 accumulation after hypoxic stress. Moreover, forced expression of CHIP prevented hypoxia-induced cardiomyocyte apoptosis by inducing degradation of p53, suggesting that CHIP-mediated p53 degradation is a potential therapeutic target.
17-AAG Protects Cardiomyocytes From Hypoxia-Induced Apoptosis
Inhibitors for heat shock protein (Hsp)90 have been shown to promote proteasomal degradation of CHIP client proteins and to be effective for the diseases caused by the accumulation of CHIP substrates. 31, 32 We therefore examined whether an Hsp90 inhibitor 17-allylamino-17-demethoxy geldanamycin (17-AAG) induces degradation of p53 protein and protects cardiomyocytes from hypoxic stress. In cardiomyocytes treated with CoCl 2 , 17-AAG downregulated p53 expression ( Figure 4D ). 17-AAG treatment also suppressed hypoxiainduced cardiomyocyte apoptosis in a CHIP-dependent manner, because CHIP knockdown attenuated the protective effects of 17-AAG ( Figure 4E through 4G) . These results suggest that 17-AAG protects cardiomyocytes from hypoxic stress by promoting CHIP-mediated p53 degradation.
Interestingly, protein level of CHIP was increased by 17-AAG treatment ( Figure 4E ). As mRNA level of CHIP was not changed by 17-AAG treatment (Online Figure IV, A) , we speculated that protein stability was affected by 17-AAG treatment. When protein translation was inhibited by cycloheximide, 17-AAG treatment dramatically extended the protein half-life of CHIP (Online Figure IV, B and C) . 17-AAG also upregulated the protein stability of other proteins, Hsp70 and HSF-1 (Online Figure IV, B and C) . Because 17-AAG exerted some antiapoptotic effects even in the cells of negligible CHIP protein level ( Figure 4E and 4F) , upregulation of these cardioprotective proteins 33, 34 might mediate part of the effects of 17-AAG. It remains to be determined how 17-AAG prolongs protein half-life of certain kinds of proteins.
CHIP and 17-AAG Prevent Apoptosis and Ventricular Remodeling After Myocardial Infarction
We next examined whether promotion of CHIP-mediated p53 degradation could attenuate ischemic cardiac injury also in vivo. For this purpose, transgenic mice which overexpress CHIP specifically in the heart (CHIP-Tg) ( Figure 5A ) were subjected to permanent coronary artery ligation. In CHIP-Tg mice, elevation of p53 protein levels ( Figure 5B ) and apoptotic cardiomyocyte death in the border zone of the infarct area ( Figure 5B and 5C) were attenuated compared to wild-type littermates at 24 hours after the MI operation. Apoptotic death of the cardiomyocytes in the remote zone of the infarct was not changed between littermates (data not shown). We next examined whether this decrease in apoptotic cell death leads to attenuation of cardiac ventricular remodeling. At day 14, CHIP-Tg mice exhibited smaller heart weight/body weight (HW/BW) ratio, better contractility and less ventricular remodeling ( Figure 5D and 5E) compared to wild-type littermates. These results provides an evidence for our hypothesis that CHIP downregulation is responsible for p53 accumulation after myocardial infarction, and suggests that CHIP overexpression is protective for the heart by preventing p53 accumulation and cardiomyocyte apoptosis after myocardial infarction. We also examined whether treatment with 17-AAG exerts similar cardioprotective effects. 17-AAG (10 mg/kg) or vehicle was intraperitoneally injected immediately after permanent coronary artery ligation. This single injection of 17-AAG effectively suppressed the elevation of p53 protein levels and apoptotic cell death in the border zone of the infarct area at 24 hours after the operation (Figure 6A and 6B) . As p53 protein level was kept elevated even 4 and 7 days after MI ( Figure 2B ), 17-AAG was injected every other days and we assessed whether 17-AAG treatment also leads to attenuation of ventricular remodeling, as observed in CHIP-Tg mice. At day 14, mice treated with 17-AAG exhibited smaller HW/BW ratio, better contractility, and less ventricular remodeling ( Figure 6C and 6D) . Interestingly, the effects of 17-AAG were greater than CHIP overexpression (compare Figures 5 and 6 ), suggesting that 17-AAG possesses cardioprotective activities that do not involve CHIPmediated p53 degradation. As protein stability of cardioprotective proteins such as Hsp70 and HSF-1 was increased in vitro (Online Figure IV, B and C) , we have examined the expression of these proteins in 17-AAG-treated mice. As expected, expression of these two proteins were increased by 17-AAG treatment (Online Figure IV, D) , indicating that 17-AAG exerts its antiapoptotic effects by at least two mechanisms, one by inducing CHIP-mediated p53 degradation and the other by increasing cardioprotective heat shock proteins. Finally, we examined the contribution of CHIP-mediated p53 degradation on the cardioprotective effects of 17-AAG. For that purpose we used CHIP heterozygous mice. There were no differences in cleaved PARP level ( Figure 7A ; compare WT Sham and Het Sham) or cardiac function between CHIP heterozygous mice and wild-type littermates at the basal level (Table) . Following coronary artery ligation, however, apoptotic cell death was observed more prominently in CHIP heterozygous mice as assessed by increased cleaved PARP level ( Figure  7A ; compare WT MI and Het MI) and increased TUNEL positive cells ( Figure 7B ). The level of p53 accumulation was comparable following myocardial infarction between wild-type and CHIP heterozygous mice, suggesting the presence of p53 independent mechanisms for enhanced apoptosis caused by CHIP haploinsufficiency. Chronically, CHIP heterozygous mice showed worse cardiac function and worse ventricular remodeling compared with wild-type mice ( Figure 7C and 7D ). 17-AAG treatment was less effective to reduce p53 protein level, cleaved PARP level ( Figure 7A ; compare Het MI and Het MI 17-AAG), and TUNEL positive cardiomyocytes in CHIP heterozygous mice, possibly as a result of CHIP haploinsufficiency. 17-AAG treatment had minimal effects on improvements of cardiac function and ventricular remodeling on CHIP heterozygous mice also in the chronic phase ( Figure 7C and 7D) .
However, we must emphasize that the effects of 17-AAG were not fully attributable to CHIP-mediated p53 degradation because upregulation of heat shock proteins by 17-AAG was also impaired in CHIP heterozygous mice ( Figure 7A ; compare WT MI 17-AAG and Het MI 17-AAG). Therefore, it would be fair to conclude that 17-AAG exerts multiple cardioprotective effects after myocardial infarction and at least one of its effects were mediated by promotion of CHIP-mediated p53 degradation.
Discussion
In the present study, we found that accumulation of p53 protein after myocardial ischemia is initiated by HIF-1 dependent downregulation of CHIP level. We have found that CHIP overexpression decreased the amount of p53 and prevented myocardial apoptosis and ameliorated ventricular remodeling after myocardial infarction. We have also found that Hsp90 inhibitor, 17-AAG, exerted similar antiapoptotic and cardioprotective effects after myocardial infarction and showed that these effects of 17-AAG was at least in part mediated by promotion of CHIP-mediated p53 degradation.
Although hypoxic stimuli have been reported to raise p53 protein levels in a variety of cell types, molecular mechanisms of p53 accumulation have been largely unknown. In the present study, we unveiled that downregulation of CHIP protein is critically involved in this process. We found that CHIP expression was downregulated after hypoxic stress through HIF-1mediated suppression of CHIP promoter (Figure 2 ). We also found that overexpression of CHIP attenuated the p53 accumulation after hypoxic stress ( Figures 4A and 5B) . These results suggest that hypoxic stress downregulates CHIP, leading to decreased CHIP-mediated proteolysis of p53 protein and accumulation of p53 protein. This mechanism seems to be a 'fine-tuning' of HIF-1 activity because p53 protein has been reported to bind to and inhibit HIF-1 activity. 16 After hypoxia, first HIF-1 accumulates and induces angiogenic genes, to promote angiogenesis. Thereafter, as a negative feedback loop, HIF-1 induces downregulation of CHIP expression and p53 accumulates, then accumulated p53 inhibits HIF-1 activity. 35 In general, this feedback system might have an antitumor effect, because in many tumor cells HIF-1 induces feeding vessels in hypoxic tumors and promotes tumor growth. HIF-1-induced, CHIP-mediated p53 accumulation acts to suppress tumor growth by (1) suppressing HIF-1 activity and blocking neovascularization and (2) inducing p53-mediated apoptosis of tumor cells. However, in the heart, this negative feedback system worsens hypoxic situation by blocking neovascularization 16 and by inducing apoptosis (this study).
The important role of apoptosis in the progression of ventricular remodeling and the possibility of antiapoptotic approach against heart failure has already been elegantly shown by Wencker et al. 3 Antiapoptotic approach after myocardial infarction has been reported to be cardioprotective not only in ischemia-reperfusion model but also in permanent coronary ligation model. 21, 36, 37 Therefore, inhibition of apoptotic death does not only reduce initial infarct size but also prevents ventricular remodeling through inhibiting apoptosis in the border zone of the infarct.
Accumulation of p53 has been reported to initiate many proapoptotic triggers. 38 In the heart, p53 accumulates ( Figure  3C ) and p53-dependent apoptosis occurs 39 after permanent coronary occlusion. We have also observed that p53 gene deletion lead to less ventricular remodeling after myocardial infarction. 16 In the present study, we have shown that CHIP overexpression or 17-AAG treatment could prevent cardiomyocyte apoptosis and ameliorate ventricular remodeling after myocardial infarction. We have also shown some evidences that inhibition of p53 accumulation is at least one of the mechanisms for the effect of CHIP overexpression and 17-AAG. However, it should be noted that Hsp90 chaperones various proteins including prosurvival factors such as Akt/protein kinase B 40 in tumor cells and that Hsp90 inhibitors induced degradation of aberrantly overexpressed prosurvival factors in those tumor cells. Although the nature of the effects of 17-AAG seems to induce degradation of aberrantly expressed proteins, it is also possible and taken into account that 17-AAG could also induce degradation of prosurvival factors and play detrimental effects in cardiomyocytes.
In conclusion, our observations indicate that investigation of novel anti-p53 approach would open a way toward new treatment of myocardial infarction.
